Clinical Trials Logo

Filter by:
NCT ID: NCT05213065 Not yet recruiting - Clinical trials for Post-Traumatic Headache

Assessment of the Efficacy of the Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Daily Headache in Children and Adolescents.

SPG
Start date: February 5, 2022
Phase: N/A
Study type: Interventional

Primary Objective The primary objective of the study is to assess whether transnasal sphenopalatine ganglion block using the device TX360 reduces intensity and severity of the Post-Traumatic Headache in adolescents. Secondary Objectives The study will also evaluate: - Quality of life (QoL) - Intensity of the headache - Physical function - Sleep quality - Role function (measured by PEDMIDAS) - Adverse events

NCT ID: NCT05212831 Completed - COVID-19 Clinical Trials

Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study.

RESTORE
Start date: June 8, 2022
Phase: N/A
Study type: Interventional

A prospective, open label, randomized, crossover, pilot, exploratory study to describe the effect of the Inogen One® G4 POC on brain hypoxia, peripheral oxygen saturation and cognitive function in adults with longterm- COVID.

NCT ID: NCT05212792 Recruiting - Clinical trials for Vaccine Adverse Reaction

Genomics and COVID-19 Vaccine Adverse Events

Start date: June 24, 2022
Phase:
Study type: Observational

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide. Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events. The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).

NCT ID: NCT05212727 Suspended - Clinical trials for Neurological Disorders

Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders

Start date: April 15, 2022
Phase:
Study type: Observational

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by neurological disorders and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of neurological disorders and associated cognitive changes.

NCT ID: NCT05211960 Active, not recruiting - Mental Disorder Clinical Trials

Effects of a Mindfulness App for Outpatients Waitlisted for Psychological Interventions

Start date: January 24, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate a mindfulness-based meditation app provided to outpatients (or community participants) who are waitlisted for standard psychological care for mental health or substance use concerns.

NCT ID: NCT05211947 Recruiting - Schizophrenia Clinical Trials

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Start date: March 3, 2022
Phase: Phase 3
Study type: Interventional

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.

NCT ID: NCT05211895 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

PACIFIC-8
Start date: February 18, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

NCT ID: NCT05211778 Active, not recruiting - Clinical trials for Head and Neck Cancer

Digital Patient Education Platform in Head and Neck Cancer

Start date: January 8, 2019
Phase: N/A
Study type: Interventional

Head and neck cancer is a disease that has a particular propensity for treatment-related morbidity. It is hypothesized that patients who are more involved in their care in hospital and who are actively provided with more treatment-related education may report increased satisfaction and have improved overall outcomes. The investigators aim to determine whether delivery of patient-centred education in a multimedia format via a digital platform has an impact on overall satisfaction and perceived quality of medical care.

NCT ID: NCT05211206 Recruiting - ERCP Clinical Trials

IV Fluids and Post-ERCP Pancreatitis

Start date: January 10, 2022
Phase:
Study type: Observational

Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).

NCT ID: NCT05211128 Completed - Surgery Clinical Trials

The Evolving Use of Robotic Surgery

Start date: July 1, 2018
Phase:
Study type: Observational

A retrospective, population-based analysis examining the rates of robotic surgery between the years of 2009 - 2018.